Karolina Piasecka-Stryczynska - Department of Neurology and Cerebrovascular Diseases, Poznan University of Medical Sciences

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 21 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial

Stewart J. Tepper,David W. Dodick, Michel Lanteri-Minet,David Dolezil,Raquel Gil-Gouveia,Christian Lucas,Karolina Piasecka-Stryczynska, Gyoengyi Szabo,Daniel D. Mikol,Mahan Chehrenama,Denise E. Chou, Yiping Yang,Gabriel Paiva da Silva Lima

JAMA NEUROLOGY (2024)

引用0浏览0WOS引用

Efficacy and Safety Results after >3.5 Years of Treatment with the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis: Long-term Follow-Up of a Phase II Randomised Clinical Trial with a Cerebrospinal Fluid Sub-Study

Xavier Montalban,Karolina Piasecka-Stryczynska,Jens Kuhle,Pascal Benkert,Douglas L. Arnold,Martin S. Weber,Andrea Seitzinger,Hans Guehring,Jamie Shaw,Davorka Tomic,Yann Hyvert,Danielle E. Harlow,Martin Dyroff,Jerry S. Wolinsky

MULTIPLE SCLEROSIS JOURNAL（2024）

引用0浏览0WOS引用

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension

X. Montalban,J. S. Wolinsky,D. L. Arnold,M. S. Weber,K. Piasecka-Stryczynska,D. Tomic,A. Seitzinger,H. Guehring

NEUROLOGYno. 17 (2023): 53-53

引用0浏览0引用

Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic

Adam Stepien,Aleksandra Pogoda-Wesolowska,Elzbieta Tokarz-Kupczyk,Agnieszka Slowik,Przemyslaw Puz,Monika Adamczyk-Sowa,Iwona Kurkowska-Jastrzebska,Alina Kulakowska,Monika Chorazy,Karolina Piasecka-Stryczynska,Anna Jamroz-Wisniewska,Halina Bartosik-Psujek,Konrad Rejdak

NEUROLOGIA I NEUROCHIRURGIA POLSKAno. 4 (2023): 371-378

引用0浏览0WOS引用

Clinical outcomes with evobrutinib in relapsing MS up to 4 years of treatment: an ongoing Phase 2 open-label extension

X. Montalban,D. Arnold, M. Weber,K. Piasecka-Stryczynska,D. Tomic, A. Kinkolykh, Y. Li,H. Guehring,J. Wolinsky

EUROPEAN JOURNAL OF NEUROLOGY (2023): 248-248

引用0浏览0引用

Systematic Review and Network Meta-Analysis (NMA) for Cladribine Tablets in Achieving Sustained Disability Improvement (SDI) in Multiple Sclerosis

Karolina Piasecka-Stryczyńska,Łukasz Kaczyński,Mirosław Rolka,Mónika Homa,Wojciech Staśkiewicz, Piotr Paczwa,Rafał Wójcik,Marcin Piotr Kaczor,Konrad Rejdak

Neurologia i Neurochirurgia Polska（2022）

引用2浏览0引用

Safety/efficacy of evobrutinib, a Bruton's tyrosine kinase inhibitor, 2.5 years into Phase II MS open-label extension

X. Montalban,J. Wolinsky,D. Arnold,M. Weber,I. Staikov,K. Piasecka-Stryczynska,D. Tomic,E. Martin, K. Holmberg,H. Guehring

EUROPEAN JOURNAL OF NEUROLOGY（2022）

引用0浏览0引用

Taux De Poussées Chez Les Patients Atteints De SEP Rémittente Traités Par Evobrutinib, Un Inhibiteur De La BTK : Résultats D’extension De L’étude De Phase II

Xavier Montalban,Douglas Arnold,Martin S. Weber,Ivan Staikov,Karolina Piasecka-Stryczynska,Emily Martin,Jerry S. Wolinsky

Revue Neurologique（2021）

引用0浏览0引用

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study

Xavier Montalban,Douglas L. Arnold,Martin S. Weber,Ivan Staikov,Karolina Piasecka-Stryczynska,Emily C. Martin,Matthew Mandel,Yulia Zima,Jamie Shaw,Fernando Dangond,Roland Grenningloh,Ying Li,Davorka Tomic,Jerry S. Wolinsky

NEUROLOGY（2021）

引用1浏览0引用

Concentration of Evobrutinib, a BTK Inhibitor, in Cerebrospinal Fluid During Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Karolina Piasecka-Stryczynska,Konrad Rejdak,Martin Dyroff,Yann Hyvert, Kristina Holmberg,Matthew Mandel, Carolina Cunha,David Mitchell,Emily Martin,Xavier Montalban

Multiple sclerosis and related disorders (2021): 103001-103001

引用5浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn